vs
MESA LABORATORIES INC（MLAB）とPerimeter Solutions, Inc.（PRM）の財務データ比較。上の社名をクリックして会社を切り替えられます
Perimeter Solutions, Inc.の直近四半期売上が大きい（$102.8M vs $65.1M、MESA LABORATORIES INCの約1.6倍）。MESA LABORATORIES INCの純利益率が高く（5.6% vs -136.5%、差は142.1%）。Perimeter Solutions, Inc.の前年同期比売上増加率が高い（19.2% vs 3.6%）。MESA LABORATORIES INCの直近四半期フリーキャッシュフローが多い（$18.0M vs $11.6M）。過去8四半期でPerimeter Solutions, Inc.の売上複合成長率が高い（31.9% vs 5.1%）
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
ペリメーターソリューションズはイスラエル発のクラウド・ネットワークセキュリティ企業で、ゼロトラストアーキテクチャに基づいた安全なリモートネットワークを各組織向けに開発しています。同社の技術はVPNやファイアウォールといった従来のセキュリティ機器の代替を実現します。
MLAB vs PRM — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $65.1M | $102.8M |
| 純利益 | $3.6M | $-140.2M |
| 粗利率 | 64.2% | 45.2% |
| 営業利益率 | 12.2% | -160.7% |
| 純利益率 | 5.6% | -136.5% |
| 売上前年比 | 3.6% | 19.2% |
| 純利益前年比 | 316.6% | -197.3% |
| EPS（希薄化後） | $0.65 | $-0.89 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $65.1M | $102.8M | ||
| Q3 25 | $60.7M | $315.4M | ||
| Q2 25 | $59.5M | $162.6M | ||
| Q1 25 | $62.1M | $72.0M | ||
| Q4 24 | $62.8M | $86.2M | ||
| Q3 24 | $57.8M | $288.4M | ||
| Q2 24 | $58.2M | $127.3M | ||
| Q1 24 | $58.9M | $59.0M |
| Q4 25 | $3.6M | $-140.2M | ||
| Q3 25 | $2.5M | $-90.7M | ||
| Q2 25 | $4.7M | $-32.2M | ||
| Q1 25 | $-7.1M | $56.7M | ||
| Q4 24 | $-1.7M | $144.2M | ||
| Q3 24 | $3.4M | $-89.2M | ||
| Q2 24 | $3.4M | $21.6M | ||
| Q1 24 | $-254.6M | $-82.6M |
| Q4 25 | 64.2% | 45.2% | ||
| Q3 25 | 61.5% | 63.1% | ||
| Q2 25 | 62.0% | 62.4% | ||
| Q1 25 | 61.8% | 39.1% | ||
| Q4 24 | 63.3% | 48.6% | ||
| Q3 24 | 61.3% | 62.8% | ||
| Q2 24 | 64.0% | 57.6% | ||
| Q1 24 | 62.1% | 35.1% |
| Q4 25 | 12.2% | -160.7% | ||
| Q3 25 | 7.8% | -27.7% | ||
| Q2 25 | 5.1% | -16.1% | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 9.2% | 71.1% | ||
| Q3 24 | 6.1% | -12.2% | ||
| Q2 24 | 9.6% | 35.4% | ||
| Q1 24 | -460.6% | -126.8% |
| Q4 25 | 5.6% | -136.5% | ||
| Q3 25 | 4.1% | -28.7% | ||
| Q2 25 | 8.0% | -19.8% | ||
| Q1 25 | -11.4% | 78.7% | ||
| Q4 24 | -2.7% | 167.2% | ||
| Q3 24 | 5.9% | -30.9% | ||
| Q2 24 | 5.8% | 17.0% | ||
| Q1 24 | -432.2% | -139.8% |
| Q4 25 | $0.65 | $-0.89 | ||
| Q3 25 | $0.45 | $-0.62 | ||
| Q2 25 | $0.85 | $-0.22 | ||
| Q1 25 | $-1.30 | $0.36 | ||
| Q4 24 | $-0.31 | $1.00 | ||
| Q3 24 | $0.63 | $-0.61 | ||
| Q2 24 | $0.62 | $0.14 | ||
| Q1 24 | $-47.26 | $-0.57 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $29.0M | $325.9M |
| 総負債低いほど良い | $68.4M | $669.1M |
| 株主資本純資産 | $186.7M | $1.1B |
| 総資産 | $434.8M | $2.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.37× | 0.59× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $29.0M | $325.9M | ||
| Q3 25 | $20.4M | $340.6M | ||
| Q2 25 | $21.3M | $140.7M | ||
| Q1 25 | $27.3M | $200.1M | ||
| Q4 24 | $27.3M | $198.5M | ||
| Q3 24 | $24.3M | $223.1M | ||
| Q2 24 | $28.5M | $43.2M | ||
| Q1 24 | $28.2M | $38.7M |
| Q4 25 | $68.4M | $669.1M | ||
| Q3 25 | $69.4M | $668.8M | ||
| Q2 25 | $70.3M | $668.4M | ||
| Q1 25 | $71.3M | $668.1M | ||
| Q4 24 | $72.2M | $667.8M | ||
| Q3 24 | $73.1M | $667.4M | ||
| Q2 24 | $74.1M | $667.1M | ||
| Q1 24 | — | $666.8M |
| Q4 25 | $186.7M | $1.1B | ||
| Q3 25 | $178.5M | $1.1B | ||
| Q2 25 | $172.5M | $1.2B | ||
| Q1 25 | $159.8M | $1.2B | ||
| Q4 24 | $155.2M | $1.2B | ||
| Q3 24 | $161.5M | $1.0B | ||
| Q2 24 | $150.7M | $1.1B | ||
| Q1 24 | $145.4M | $1.1B |
| Q4 25 | $434.8M | $2.7B | ||
| Q3 25 | $430.4M | $2.6B | ||
| Q2 25 | $435.7M | $2.5B | ||
| Q1 25 | $433.3M | $2.4B | ||
| Q4 24 | $433.3M | $2.4B | ||
| Q3 24 | $454.1M | $2.5B | ||
| Q2 24 | $440.4M | $2.3B | ||
| Q1 24 | $446.8M | $2.3B |
| Q4 25 | 0.37× | 0.59× | ||
| Q3 25 | 0.39× | 0.60× | ||
| Q2 25 | 0.41× | 0.57× | ||
| Q1 25 | 0.45× | 0.55× | ||
| Q4 24 | 0.47× | 0.58× | ||
| Q3 24 | 0.45× | 0.67× | ||
| Q2 24 | 0.49× | 0.62× | ||
| Q1 24 | — | 0.63× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $18.8M | $18.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $18.0M | $11.6M |
| FCFマージンFCF / 売上 | 27.7% | 11.3% |
| 設備投資強度設備投資 / 売上 | 1.1% | 6.8% |
| キャッシュ転換率営業CF / 純利益 | 5.17× | — |
| 直近12ヶ月FCF直近4四半期 | $37.9M | $208.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $18.8M | $18.6M | ||
| Q3 25 | $8.2M | $198.7M | ||
| Q2 25 | $1.9M | $-2.9M | ||
| Q1 25 | $12.7M | $23.7M | ||
| Q4 24 | $18.1M | $-6.0M | ||
| Q3 24 | $5.3M | $183.0M | ||
| Q2 24 | $10.7M | $8.6M | ||
| Q1 24 | $12.9M | $2.8M |
| Q4 25 | $18.0M | $11.6M | ||
| Q3 25 | $7.1M | $193.6M | ||
| Q2 25 | $884.0K | $-15.6M | ||
| Q1 25 | $11.9M | $18.9M | ||
| Q4 24 | $17.3M | $-12.4M | ||
| Q3 24 | $3.5M | $179.1M | ||
| Q2 24 | $9.9M | $5.0M | ||
| Q1 24 | $12.3M | $1.2M |
| Q4 25 | 27.7% | 11.3% | ||
| Q3 25 | 11.7% | 61.4% | ||
| Q2 25 | 1.5% | -9.6% | ||
| Q1 25 | 19.2% | 26.3% | ||
| Q4 24 | 27.6% | -14.4% | ||
| Q3 24 | 6.0% | 62.1% | ||
| Q2 24 | 16.9% | 3.9% | ||
| Q1 24 | 21.0% | 2.1% |
| Q4 25 | 1.1% | 6.8% | ||
| Q3 25 | 1.8% | 1.6% | ||
| Q2 25 | 1.7% | 7.8% | ||
| Q1 25 | 1.2% | 6.7% | ||
| Q4 24 | 1.3% | 7.5% | ||
| Q3 24 | 3.1% | 1.3% | ||
| Q2 24 | 1.5% | 2.9% | ||
| Q1 24 | 0.9% | 2.6% |
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | -0.04× | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | 0.40× | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
PRM
| Products | $87.7M | 85% |
| Service And Other | $14.8M | 14% |
